Trelstar

Trelstar is a brand name of triptorelin, approved by the FDA in the following formulation(s):

TRELSTAR (triptorelin pamoate - injectable; intramuscular)

• 
  Manufacturer: WATSON LABS
  
  Approval date: June 15, 2000
  
  Strength(s): EQ 3.75MG BASE/VIAL ^[RLD]


• 
  Manufacturer: WATSON LABS
  
  Approval date: June 29, 2001
  
  Strength(s): EQ 11.25MG BASE/VIAL ^[RLD]


• 
  Manufacturer: WATSON LABS
  
  Approval date: March 10, 2010
  
  Strength(s): EQ 22.5MG BASE/VIAL ^[RLD]

Has a generic version of Trelstar been approved?

No. There is currently no therapeutically equivalent version of Trelstar available.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Trelstar. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

• 
  Sustained and controlled release of water insoluble polypeptides
  Patent 5,776,885
  Issued: July 7, 1998
  Inventor(s): Orsolini; Piero & Mauvernay; Rolland-Yves & Deghenghi; Romano
  Assignee(s): Debio Recherche Pharmaceutique SA
  A pharmaceutical composition for the sustained release of a peptide wherein the composition includes a polylactide polymer, a polymer of lactic acid and glycolic acid, or a mixture of such polymers and a therapeutically active peptide in the form of its pamoate, tannate or stearate salt. The composition when placed in an aqueous physiological environment releases the peptide in a continuous manner for a period of at least about one week.
  
  Patent expiration dates:
  
  
  • July 7, 2015
    
  
  
  
  • July 7, 2015
    
    ✓ 
    Drug product
  
  

Related Exclusivities

Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.

• Exclusivity expiration dates:
  • March 10, 2013 - NEW PRODUCT
  
  

See also...

• Trelstar Advanced Consumer Information (Micromedex)
• Trelstar AHFS DI Monographs (ASHP)
• Triptorelin Consumer Information (Wolters Kluwer)
• Triptorelin Consumer Information (Cerner Multum)
• Triptorelin Intramuscular, Injection Advanced Consumer Information (Micromedex)
• Triptorelin Pamoate AHFS DI Monographs (ASHP)